PRESSRELEASE       September 6, 2022 AegirBio AB is pleased to announce the initiation of a development and licensing agreement with iSTOC. The agreement covers the development of a data management platform for the recently CE-marked Magnia® Reader based natalizumab Point of Care (POC) therapeutic drug monitoring (TDM) test.

The deliverables will include a web-based information dashboard and a mobile app to upload data readouts from the Magnia Reader. This platform will provide an interface between electronic medical records and be a foundation for easy integration of our assays into clinical, POC, and at-home workflows, both for upcoming trials and everyday patient care.

“In modern Point of Care and Point of Need testing, data management and presentation are as important as the accuracy of the test. We reviewed many potential solutions and ultimately chose the iSTOC platform because of its flexibility, data security, and established regulatory compliance.” said Bradley Messmer, CEO of AegirBio.

He added “With real world clinical studies about to begin, we identified that it was critical to get this component of our total solution in development. A successful project with this product will open the door for future collaborations with our growing portfolio of assays and we look forward to a fruitful partnership with the iSTOC team”.

Jarmo Järvenpää, the CEO of iSTOC stated “We are looking forward to developing the platform with AegirBio. We are excited to start collaborating with AegirBio and combining our strengths in this information dashboard and mobile app project, as well as in future ventures under discussion.” 

About iSTOC

iSTOC is a global player in mobile Point of Care (POC) diagnostics by transforming disconnected data into relevant and actionable information.  By integrating mobile technologies with smart services iSTOC has deployed and is deploying POC services to both consumers and professional users. IDA (Immediate Diagnostics and Analytics) Platform integrates Point of Care diagnostics, AI, mobile technology and cloud computing into one reliable platform, which ensures that accurate data is immediately available and actionable. www.istoc.io.

About AegirBio

AegirBio is a Swedish diagnostics company that was founded in 2019 to offer tests to monitor and optimize the dosage of biological drugs via its unique patented technology platform. In June 2020, AegirBio was listed on the Nasdaq First North Growth Market. The company's ambition is, in addition to bringing innovative diagnostic technology to the market, to make diagnostics more accessible, easier to use and to provide accurate and easily transferable results.

Related links:
Release
Cision